[ACTION OF L-CARNITINE, CORVITIN AND THEIR COMBINATION ON FUNCTIONAL STATE OF LIVER IN EXPERIMENTAL MODEL OF REYE...

Area of Science:

• Biochemistry
• Toxicology
• Pharmacology

Background:

• Reye syndrome, a severe condition linked to aspirin administration during viral infections in children, is characterized by encephalopathy and liver insufficiency.
• Carnitine deficiency and hepatocyte damage are critical factors in Reye syndrome pathogenesis, impairing mitochondrial function, gluconeogenesis, and urea production.
• This leads to toxic encephalopathy and liver failure, highlighting the need for effective therapeutic interventions.

Purpose of the Study:

• To evaluate the efficacy of L-Carnitine, Corvitin, and their combination in ameliorating liver dysfunction in an experimental rat model of Reye syndrome.
• To assess the impact of these interventions on key indicators of liver function, including hepatocyte damage, glucose and urea levels, and cholestasis markers.

Main Methods:

• A Reye syndrome model was induced in Wistar rats using daily intraperitoneal administration of 4-pentenoic acid (20mg/kg) for seven days.
• Treated groups received intraperitoneal L-Carnitine (300mg/kg), Corvitin (100mg/kg), or a combination of both.
• Liver function was assessed by monitoring hepatocyte cytolysis indicators, glucose and urea levels, and cholestasis markers.

Main Results:

• Both L-Carnitine and Corvitin monotherapy significantly improved liver function, reducing hepatocyte damage markers and increasing glucose and urea levels.
• L-Carnitine showed a slightly greater improvement in cholestasis markers compared to Corvitin.
• The combination therapy demonstrated a pronounced hepatoprotective effect, normalizing liver damage indicators and resulting in no mortality among the treated rats.

Conclusions:

• Concurrent administration of L-Carnitine and Corvitin exhibits significant synergistic hepatoprotective effects in the Reye syndrome rat model.
• This combined therapeutic approach effectively corrects liver function and prevents mortality, suggesting its potential clinical recommendation for Reye syndrome management.
• Further research into the synergistic mechanisms underlying this combined therapy is warranted.